Publications by authors named "Bedossa Pierre"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

32,052

Total Likes

1,905

Extended Reach

2,092,114

Social Features

232
E
Expert Delphi consensus on surrogate endpoints for treatment assessment in metabolic dysfunction-associated steatohepatitis.
Arun J Sanyal, Atsushi Nakajima, Elisabetta Bugianesi, Giada Sebastiani, Jörn M Schattenberg, Pierre Bedossa

Clin Gastroenterol Hepatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials.
Carolin Lackner, Annette S H Gouw, Venancio Avancini Ferreira Alves, Johanna Arola, Pierre Bedossa

J Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fat-Corrected Non-Gaussian Diffusion MRI for Liver Fibrosis Assessment in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Omaïma Saïd, Sabrina Doblas, Valérie Paradis, Pierre Bedossa, Dominique Valla

J Magn Reson Imaging· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AI portal tract detection and characterisation for a regional analysis of steatosis and inflammation in MASLD, MASH and AIH.
Dylan Windell, Alastair Magness, Cayden Beyer, Helena Thomaides Brears, Sarah Larkin, Pierre Bedossa

J Clin Pathol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Morphometric Quantification of Steatosis and Fibrosis in Metabolic Liver Disease Associated With Type 2 Diabetes.
Oliver Fourati, Pauline Manchon, Phillipe Garteiser, Laurent Castera, Marco Dioguardi Burgio, Pierre Bedossa

Clin Gastroenterol Hepatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Mazen Noureddin, Juan P Frias, Guy W Neff, K Jean Lucas, Cynthia Behling, Pierre Bedossa

Lancet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment.
Pierre-Emmanuel Rautou, Shivani Chotkoe, Louise Biquard, Guillaume Wettstein, Denise van der Graaff, Pierre Bedossa, Pierre Broqua

JHEP Rep· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Thierry Poynard, Olivier Deckmyn, Raluca Pais, Judith Aron-Wisnewsky, Valentina Peta, Pierre Bedossa

Diagnostics (Basel)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver Disease Complicating Familial Mediterranean Fever: A Study on 66 Patients Out of 533 Adult From the JIR Cohort.
Marion Delplanque, Xavier Amiot, Dominique Wendum, François Rodrigues, Zohra Aknouche, Pierre Bedossa

Liver Int· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial.
Rohit Loomba, Pierre Bedossa, Katharine Grimmer, George Kemble, Eduardo Bruno Martins

Lancet Gastroenterol Hepatol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic and hepatic phenotypes in sarcopenic obesity and impact of bariatric surgery.
Vittoria Zambon Azevedo, Pierre Bel Lassen, Judith Aron-Wisnewsky, Laurent Genser, Frederic Charlotte, Pierre Bedossa

Clin Nutr· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood-based MASH diagnostic in candidates for bariatric surgery using mid-infrared spectroscopy: a European multicenter prospective study.
Maëna Le Corvec, Marwin A Farrugia, Eric Nguyen-Khac, Jean-Marc Régimbeau, Abdennaceur Dharhri, Jean-Pierre Bronowicki, Pierre Bedossa

Sci Rep· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe acute liver disease in adults: Contemporary role of histopathology.
Andrew D Clouston, Annette S H Gouw, Dina Tiniakos, Pierre Bedossa, Elizabeth M Brunt

Histopathology· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Choline-deficient, high-fat diet-induced MASH in Göttingen Minipigs: characterization and effects of a chow reversal period.
Henning Hvid, Sara T Hjuler, Pierre Bedossa, Dina G Tiniakos, Ioannis Kamzolas

Am J Physiol Gastrointest Liver Physiol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen.
Anu Sharma, Eddison Godina Leiva, Srilaxmi Kalavalapalli, Romina Lomonaco, Stephen A Marangi, Pierre Bedossa

Obesity (Silver Spring)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a whole slide image management system for metabolic-associated steatohepatitis for clinical trials.
Hanna Pulaski, Shraddha S Mehta, Laryssa C Manigat, Stephanie Kaufman, Hypatia Hou, Pierre Bedossa

J Pathol Clin Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
Laurent Castera, Philippe Garteiser, Cédric Laouenan, Tiphaine Vidal-Trécan, Anaïs Vallet-Pichard, Pierre Bedossa

J Hepatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AI Digital Pathology Using qFibrosis Shows Heterogeneity of Fibrosis Regression in Patients with Chronic Hepatitis B and C with Viral Response.
Feng Liu, Yameng Sun, Dean Tai, Yayun Ren, Elaine L K Chng, Pierre Bedossa

Diagnostics (Basel)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
Arun J Sanyal, Pierre Bedossa, Mandy Fraessdorf, Guy W Neff, Eric Lawitz

N Engl J Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD).
Michele Vacca, Ioannis Kamzolas, Lea Mørch Harder, Fiona Oakley, Christian Trautwein, Pierre Bedossa

Nat Metab· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Comparison of Attenuation Imaging and Controlled Attenuation Parameter for Liver Steatosis Diagnosis in Patients With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes.
Marco Dioguardi Burgio, Laurent Castera, Mehdi Oufighou, Pierre-Emmanuel Rautou, Valérie Paradis, Pierre Bedossa

Clin Gastroenterol Hepatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH.
Markus Boesch, Andreas Lindhorst, Rita Feio-Azevedo, Paola Brescia, Alessandra Silvestri, Pierre Bedossa

J Hepatol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.
Stephen A Harrison, Vlad Ratziu, Quentin M Anstee, Mazen Noureddin, Arun J Sanyal, Pierre Bedossa

Aliment Pharmacol Ther· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Stephen A Harrison, Juan P Frias, Guy Neff, Gary A Abrams, K Jean Lucas, Pierre Bedossa

Lancet Gastroenterol Hepatol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis